Search
Lesinurad
go.drugbank.com/drugs/DB11560ApprovedWithdrawnLesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptak...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersInsulin tregopil
go.drugbank.com/drugs/DB11568InvestigationalCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersElbasvir
go.drugbank.com/drugs/DB11574ApprovedElbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). HCV is a single-stranded RNA virus that is c...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesLifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalLifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through...
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsRupatadine
go.drugbank.com/drugs/DB11614ApprovedInvestigationalRupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesTucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalTucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tuca...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsTreosulfan
go.drugbank.com/drugs/DB11678ApprovedInvestigationalTreosulfan is a prodrug alternative to busulfan for myeloablative conditioning prior to hematopoietic stem cell transplantation. It was approved by the EMA in June 2019 and by the FDA in January 2025 for use in combination with fludarabine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsTezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigationalAlterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes. … [A20298,A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesRibociclib
go.drugbank.com/drugs/DB11730ApprovedInvestigationalRibociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can e...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsBryostatin 1
go.drugbank.com/drugs/DB11752InvestigationalBryostatin 1 has been investigated for the treatment of HIV Infection and Alzheimer's Disease.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors